What Is New - Spondyloarthritis and Psoriatic Arthritis

Take a look at our 'What is new' highlights in spondyloarthritis and psoriatic arthritis!

February 2023

"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-╬▒ inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)"

Why WIN?

The data from the BE-OPTIMAL and BE-COMPLETE phase 3 trials of Bimekizumab als monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17 A AND F in PsA patients are really promising and especially the response rates in TNF-i inadequate responders from the BE-COMPLETE study are indicating a new important therapeutic option, especially in those patients that are usually complicated to manage in our clinical routine. This in combination with the promising data from dedicated RCTs in skin Psoriasis are pointing out the potential of this new mode of action

Interactive question

Will the availability of dual IL-17 A&F inhibition change your clinical practice of treating patients with psoriatic diseases?

Yes, this might become my preferred choice for PsO/PsA patients

No, but still good to have as alternative option

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

January 2023

"Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin"

Why WIN?

The ┬┤holy-grail` of research in psoriatic diseases is how to identify those patients with skin psoriasis (PsO), that will develop musculoskeletal manifestations of a Psoriatic Arthritis (PsA) over time. This fascinating study from the working group of Jose Scher found  differences in the skin microbiome between healthy individuals and patients with psoriatic diseases. Furthermore, differences in the cutaneous microbiota between PsO and PsA patients might open new opportunities to identify PsO patients at risk for developing musculoskeletal involvement

Interactive question

Is the identification of PsO patients at risk for developing PsA clinically relevant from your perspective?

Yes, as this could lead to an intisified treatment approach in PsO patients

No, as treatment will still be initiated when clinical musculoskeletal symptoms are evident

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

December 2022

"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update"

Why WIN?

Here you can find the evidence based update of the international management recommendations for axial SpA of ASAS and EULAR. Get updated about the newest advances regarding all related topics of the management of your clinical routine taking care of patients with axial SpA. From diagnosis, disease activity assessment, patient education to pharmacological as well as non-pharmacological interventions!

Interactive question

What is the most important point for you on the research agenda of axial SpA?

    1. New treatment targets

    2. Disease specific biomarkers

    3. Comorbidities

    4. How to treat from target?

    5. Something else. Please explain in the comments

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

November 2022

"Deep learning algorithms for magnetic resonance imaging of inflammatory sacroiliitis in axial spondyloarthritis"

Why WIN?

Deep learning segmentation is a subset of artificial intelligence (AI) machine learning, and it currently has wide applications in various areas of medical imaging analysis. A deep learning segmentation algorithm prototype was developed for detection of MRI sacroiliitis. Performance of the AI algorithm was similar to that of the radiologist, and superior to that of the rheumatologist.

Interactive question

Do you consider that artificial intelligence machine learning algorithms may be utilized for the diagnosis of SpA and the assessment of disease activity?

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

"Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography?"

Why WIN?

The diagnosis of axial SpA is strongly imaging based. The most recent EULAR Recommmendations for Imaging in SpA suggest conventional x-ray of the sacroiliac joints (SIJs) as the primary imaging modality in suspected cases of axSpA. Recent evidence suggest clear superiority of MRI over x-ray also for the assessment of structural changes of the SIJs. This lead to the viewpoint just published in ARD. This should trigger a discussion within the community taking costs, access in different settings/geographical regions, radioation exposure and ability for early diagnosis of axSpA into account.

Interactive question

What is your preferred first imaging modality in patients with suspicion of axSpA?

a) x-ray of the SIJs

b) MRI of the SIJs

c) None of the above. Please explain in the comments

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

October 2022

"Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling"

Why WIN?

The ability to identify patients with psoriasis who are at a high risk of developing PsA is an important goal for clinical research, as this would allow early intervention to reduce the impact of PsA and ultimately lead to preventative treatments.

Interactive question

Do you consider that future research on PsA susceptibility in patients with psoriasis should combine clinical data and genetics with longitudinal prospective studies in patients with clinically well-defined PsC before treatment with biologic drugs?

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET


"Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study"

Why WIN?

Treating to target (T2T) is a well established concept in inflammatory rheumatic disease and is recommended also in SpA. But how to proceed when remission as the desired goal of treatment is achieved? In other words: how to treat from target (TFT)? Check out the recent publication on the flare rates after treatment withdrawal of IL-17Ai in axSpA and recapture rates after re-introducing treatment.

Interactive question

Is the glass half- full or half empty? How is your perspective: if you would be a patient, would you stop an effective drug if the chances of having a disease flare needing re-treatment is approx. 50%? YES or NO?

Important insights from COAST-Y: high proportion recaptured low disease activity after re-introduction of IL-17A inhibition!

Let us hear your perspectives! Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

September 2022

"Elevated Th17 cells are associated with cardiovascular complications in ankylosing spondylitis"

Why WIN?

Patients with AS exhibit increased risk of cardiovascular diseases (CVD) compared with the general population, making the long-term management a great challenge. The study aimed to examine the levels of peripheral lymphocyte and CD4+ T-cells in AS-CVD, and explore their correlations with the presence of CVD, suggesting that elevated Th17 cells may correlate with the development of CVD in AS.

Interactive question

Do you consider that the elevation in Th17 cells could be a predictive risk for developing cardiovascular diseases in AS patients and that Th17 cells and Th17-derived cytokines can be potential therapeutic targets of AS-CVD?

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET


"Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis"

Why WIN?

Under the umbrella term of Spondyloarthritis (SpA) different diseases with overlapping features are subsumed, while axial Spondyloathritis (axSpA) and Psoriatic Arthritis (PsA) are its primary representatives. The overlap between those diseases is obvoius and currently it is a matter of debate and a 'hot topic' of SpA research if axSpA and axial disease of PsA (axial PsA) are different phenotypes of the same disease or different diseases with great similarities.

Interactive question

Are axPsA and axSpA with Psoriasis the same disease just looked at from different perspectives?

Let us hear your perspectives! Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET


April 2022

March 2022

February 2022

December 2021

November 2021

October 2021

Aug 2021

Jan 2021

December 2020

November 2020

October 2020

Sep 2020